BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
Dyadic International (USA) Inc.
140 Intracoastal Pointe Drive, Suite 404
Jupiter FL 33477-5094, US
Phone: (561) 743-8333; Fax: (561) 743-8343
Web: www.dyadic-group.com; E-mail: information@dyadic-group.com
KEY PERSONNEL: Mark Emalfarb; Chairman, President and CEO
Wayne Moor; CFO
Dr. Glenn Nedwin; CSO
Kent Sproat; Exec VP, Enzymes
Ray Chandra; Sr. VP, Marketing, Biotech Systems
Alexander (Sasha) Bondar; VP, Corporate Development
Charles W. (Bill) Kling IV; VP, Sales and Marketing, Enzymes
Dan Michalopoulos, Ph.D.; VP, Pulp and Paper
Richard Burlingame, Ph.D.; Exec. Director, R&D
EMPLOYEES: 126 employees
HISTORY: Founded in 1979
STOCK-FINANCIAL HISTORY: AMEX--DIL
Revenue $15.9M (YE 05) compared to $16.7M (YE 04)
Net loss (YE 05) compared to (YE 04)
Loss per share (YE 05) compared to (YE 04)
PRIVATE PLACEMENTS: Raised $2.1M in warrants and options exercise (5/06)
SUBSIDIARIES/DIVISIONS: Enzyme Business
Biosciences Business
BUSINESS STRATEGY: Leverage its technology platform to discover novel genes and biological
products for use by its strategic partners, and to further the company’s own
R&D efforts
Seek strategic alliances with leaders in the agricultural, biological, industrial,
chemical and biopharmaceutical industries that have in-house genomic
capabilities. Collaborate with companies whose genomic capabilities are
limited in order to discover and express biological materials for these
strategic partners
Commercialize enzymes for use in targeted markets including the animal
nutrition, detergent, ethanol, pulp and paper, biopharmaceutical, starch and
textile industries
RESEARCH & DEVELOPMENT: Discover, develop and manufacture novel products derived from the DNA of
complex living organisms (including humans)
Development of biological products such as proteins, enzymes, polypeptides
and small molecules for applications in large segments of the agricultural,
industrial, chemical and biopharmaceutical industries
Discovery and expression of eukaryotic genes and manufacturing for
commercial application
Dynavax Europe
Eichsfelder Strasse 11
Dusseldorf 40595, Germany
Phone: +49 (0)211 7 58 45 0; Fax: +49 (0)211 7 58 45 130
Web: www.rheinbiotech.de
E-mail: info@rheinbiotech.de
KEY PERSONNEL: Zbigniew Janowicz, Ph.D.; CEO, Dynavax Europe
Petra Zimmer; CFO
Oliver Bartelsen, Ph.D.; Director, Business Development
EMPLOYEES: 43 employees
Copyright ©2006 AHC Media ® 149